Shin, Woo Jung; Noh, Hyun Jong; Noh, Young-Woock; Kim, Sohyun; Um, Soong Ho; Lim, Yong Taik
Carbohydrate polymers
2017Jan ; 155 ( D1 ) :1-10.
PMID : 27702491
ÀúÀÚ »ó¼¼Á¤º¸
Shin, Woo Jung -
Noh, Hyun Jong -
Noh, Young-Woock -
Kim, Sohyun -
Um, Soong Ho -
Lim, Yong Taik -
ABSTRACT
A novel powder-form combination adjuvant system containing two immunostimulatory compounds was firstly developed and evaluated as a therapeutic intervention for cancer immunotherapy. With the help of hyaluronic acid (HA), water insoluble monophosphoryl lipid A (MPL), QS21 and imiquimod (R837), could be easily dispersed in aqueous solution and lyophilized as powder-form, which have an advantage in room-temperature storage stability compared with those conventional liquid formulation that requires cold storage. Two kinds of HA-based combination vaccine adjuvants (HA/MPL/QS21, HMQ and HA/MPL/R837, HMR) contributed to the increase of both humoral and cellular immunity, which is very important for efficient cancer immunotherapy. Through the challenge experiments in EG7-OVA (mouse lymphoma-expressing OVA) tumor-bearing mice model, we found out that the immunostimulatory effects of HMQ and HMR were successful in the inhibition of tumor proliferation. Taken together, both HA-based powder-form combination adjuvant systems are expected to be used as potent prophylactic and therapeutic cancer vaccine. CI - Copyright ??2016 Elsevier Ltd. All rights reserved.
Cancer immunotherapy, Powder-form adjuvant, Immunostimulation, Hyaluronic acid, Cellular immunity
¸µÅ©